Bottom line
PRHSX vs IXJ: the short answer
PRHSX (T. Rowe Price Health Sciences Fund, Inc.) and IXJ (iShares Global Healthcare ETF) share a meaningful slice of their top holdings — about 70% by weight.
But PRHSX is far broader, holding 279 positions to 124 for IXJ, so beyond the top names it adds exposure IXJ doesn't have.
IXJ is cheaper at 0.38% vs 0.83% — a difference of $45 a year per $10,000 invested.
Over five years, IXJ returned +6.4% a year vs +4.2% for PRHSX.
Updated Nov 19, 2026
PRHSX vs IXJ side by side
| PRHSX | IXJ | |
|---|---|---|
| Type | Mutual fund | ETF |
| Fund family | T. Rowe Price | iShares |
| Category | Health Care Sector | Health Care Sector |
| Expense ratio | 0.83% | 0.38% |
| Annual cost per $10k | $83 | $38 |
| 10-yr cost on $10k (prospectus) | $1,025 | $480 |
| Max front load | — | None |
| 12b-1 fee | — | 0% |
| 1-yr return | +17.7% | +14.9% |
| 5-yr return (annualized) | +4.2% | +6.4% |
| 10-yr return (annualized) | +9.1% | +8.2% |
| Best quarter | +23.5% | +13.6% |
| Worst quarter | −15.8% | −11.8% |
| Net assets (fund) | $11.9B | $3.8B |
| Number of holdings | 279 | 124 |
| Portfolio turnover | 62% | 2% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | PRHSX | IXJ | Difference |
|---|---|---|---|
| 2025 | +17.7% | +14.9% | +2.9% |
| 2024 | +1.8% | +0.6% | +1.2% |
| 2023 | +3.1% | +3.5% | −0.4% |
| 2022 | −12.2% | −4.7% | −7.5% |
| 2021 | +13.3% | +19.5% | −6.2% |
| 2020 | +30.1% | +12.5% | +17.6% |
| 2019 | +29.1% | +23.4% | +5.8% |
| 2018 | +1.2% | +2.9% | −1.6% |
| 2017 | +28.0% | +20.3% | +7.6% |
| 2016 | −10.4% | −6.2% | −4.2% |
Source: Fund prospectus bar charts
Holdings overlap
16 of PRHSX's top 25 holdings also appear in IXJ's top 25.
| Holding | PRHSX | IXJ |
|---|---|---|
| Eli Lilly & Co | 14.28% | 10.93% |
| Johnson & Johnson | 6.63% | 7.04% |
| Unitedhealth Group Inc | 5.99% | 4.40% |
| Abbvie Inc | 5.10% | 5.12% |
| Merck & Co. Inc. | 4.01% | 4.12% |
| Gilead Sciences Inc | 2.82% | 2.04% |
| Thermo Fisher Scientific Inc | 2.52% | 2.42% |
| Vertex Pharmaceuticals Inc | 2.28% | 1.64% |
| Bristol-myers Squibb Co | 2.11% | 1.53% |
| Abbott Laboratories | 1.89% | 2.05% |
| Intuitive Surgical Inc | 1.87% | 1.83% |
| Amgen Inc | 1.82% | 2.54% |
| Stryker Corp | 1.78% | 1.41% |
| Elevance Health Inc | 1.53% | 1.09% |
| Danaher Corp | 1.43% | 1.56% |
Source: SEC Form N-PORT
PRHSX top 10
- Eli Lilly & Co — 14.28%
- Johnson & Johnson — 6.63%
- Unitedhealth Group Inc — 5.99%
- Abbvie Inc — 5.10%
- Merck & Co. Inc. — 4.01%
- Gilead Sciences Inc — 2.82%
- Thermo Fisher Scientific Inc — 2.52%
- Vertex Pharmaceuticals Inc — 2.28%
- Bristol-myers Squibb Co — 2.11%
- Abbott Laboratories — 1.89%
IXJ top 10
- Eli Lilly And Company — 10.93%
- Johnson & Johnson — 7.04%
- Abbvie Inc. — 5.12%
- Unitedhealth Group Incorporated — 4.40%
- Merck & Co., Inc. — 4.12%
- Astrazeneca Plc — 3.76%
- Roche Holding AG — 3.75%
- Novartis AG — 3.71%
- Amgen Inc. — 2.54%
- Thermo Fisher Scientific Incorporated — 2.42%
FAQ
What is the difference between PRHSX and IXJ?
Which is cheaper, PRHSX or IXJ?
Should I own both PRHSX and IXJ?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.